| Ytd | 78.74% | |
| 1y | 51.40% |
| Open | 10.14 | Prev Close | 10.22 | Low | 10.00 | High | 10.30 | Mkt Cap | 561.09M |
| Vol | 248.88K | Avg Vol | 2.00M | EPS | -0.98 | P/E | -10.43 | Forward P/E | -9.48 |
| Beta | -0.52 | Short Ratio | 7.72 | Inst. Own | 22.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 8.95 | 200-d Avg | 6.38 | 1yr Est | 19.00 |
CADL News
Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncolog
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free surviv
NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
NEEDHAM, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Candel Therapeutics NASDAQ: CADL Chief Executive Officer Dr. Paul Peter Tak said the company remains
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the
Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free su
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagen
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow
NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the anal
NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (
NEEDHAM, Mass. , May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical
NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (
NEEDHAM, Mass. , May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
The US Federal Reserve left interest rates unchanged on Wednesday, in line with market expectations,
Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how nar
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and ra
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clini
Citigroup analyst Yigal Nochomovitz maintains Candel Therapeutics (NASDAQ:CADL) with a Buy and lo
(Editor's note: The future prices of benchmark tracking ETFs, the lede, and the headline were up
During Wednesday's trading, 517 companies set new 52-week lows.
On Thursday, 588 stocks hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.